GSK plc

GSK

GB00BN7SWP63

Pharmaceuticals

Real-time Estimate Cboe Europe Other stock markets 08:15:36 15/05/2026 pm IST			5-day change	1st Jan Change
1,865.25 ^GBX	-0.39%		+1.06%	+2.08%

03:01pm	WINNERS & LOSERS: Miners slide; Centrica to pay GBP20 million to Ofgem	AN
14/05	Morningstar Upgrades GSK to Buy Rating	MT

Health Care Down on Cyclical Rotation -- Health Care Roundup

Published on 04/10/2026 at 01:29 am IST

Dow Jones

GSK PLC

-0.39%

ELI LILLY AND COMPANY

+0.45%

Health-care companies ticked down as traders rotated into cyclical sectors.

Eli Lilly's Foundayo weight-loss pill is now available in the U.S. following the Food and Drug Administration's approval earlier this month, the company said.

British drug maker GSK withdrew its application for a drug touted last year by President Trump as a potential treatment for autism symptoms, just months after the company submitted it at the request of health officials.

Write to Rob Curran at rob.curran@dowjones.com

(END) Dow Jones Newswires

04-09-26 1759ET

Stocks mentioned in the article

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Approximate price	Change	5d. change	Capi.
	GSK PLC	1,865.25GBX	-0.39%	+1.06%	10TCr
	ELI LILLY AND COMPANY	1,009.49USD	+0.45%	+6.72%	90TCr

Latest news about GSK plc

03:01pm	WINNERS & LOSERS: Miners slide; Centrica to pay GBP20 million to Ofgem	AN
14/05	Morningstar Upgrades GSK to Buy Rating	MT
14/05	UK Stocks-Factors to watch on May 14	RE
12/05	European Equities Traded in the US as American Depositary Receipts Decline Sharply in Tuesday Trading	MT
12/05	Artios Pharma Limited and GSK Enter Clinical Trial Collaboration Agreement	CI
11/05	Global markets live: Alphabet, Cerebras, Compass, GSK, Rockwool…
11/05	GSK plc and Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Enter Exclusive Collaboration for Bepirovirsen in China	CI
11/05	GSK Teams Up with Sino Biopharmaceutical for Distribution of Potential Hepatitis B Drug in China	MT
11/05	GSK, Sino Biopharmaceutical Unit Collaborate for China Launch of Bepirovirsen	MT
11/05	GSK agrees China hepatitis B deal as kicks off last tranche of buyback	AN
11/05	Compass lifts outlook as GSK expands in China	AN
11/05	GSK Kicks Off Fifth Tranche of GBP2 Billion Share Repurchase Program	MT
11/05	GSK Signs Chronic Hepatitis B Drug's Marketing Deal With China's Sino Biopharmaceutical	MT
11/05	GSK Partners With SBP to Speed Up China Rollout of Hepatitis Drug	DJ
11/05	GSK plans to sell chronic hepatitis B drug in China through Sino Biopharm	RE

Chart GSK plc

Duration

Period

GSK: Dynamic Chart

Company Profile

GSK plc is a United Kingdom-based biopharma company. The Companyâ€™s segments include Commercial Operations and Research and Development. The Company is focused on the science of the immune system and advanced technologies, investing in four core therapeutic areas-respiratory, immunology and inflammation; oncology; human immunodeficiency virus (HIV), and infectious diseases. Its specialty medicines prevent and treat diseases, from asthma, cancer and HIV to autoimmune diseases like lupus. General medicines include inhalers for asthma and chronic obstructive pulmonary disease (COPD) with antibiotics. Its portfolio also includes Efimosfermin, a fibroblast growth factor 21 (FGF21) analog therapeutic in clinical development. The Company also engaged in ozureprubart, a long-acting anti-immunoglobulin E (IgE) monoclonal antibody. The Company also owns HS235, a potential molecule for the treatment of pulmonary hypertension (PH).

Employees

66,841

Sector

Pharmaceuticals

More about the company